Go to content


We're growing a robust development and clinical program.

We have been working on several targets to prevent viral infections. We are now looking at expanding the breadth of our vaccines portfolio to eventually go beyond viral diseases. Medicago's platform can be used for both vaccine manufacturing as well as for the production of monoclonal antibodies.


Name Preclinical Phase 1 Phase 2 Phase 3 Registration
Seasonal FluRegistration
Pandemic Fluphase-2
Seasonal Flu, Adjuvantedphase-1


Zoonotic viruses with potential to infect humans.

Product Type Vaccine Antibody

What is coronavirus?

Coronaviruses (CoV) are a large family of viruses that are common in people and many different species of animals, including camels, cattle, cats, and bats. Rarely, animal coronaviruses can infect people and then spread between people such as with MERS-CoV, SARS-CoV, and now a new virus named SARS-CoV-2, which is causing the “coronavirus disease 2019” (abbreviated “COVID-19”).

Several known coronaviruses are circulating in animals and could eventually infect humans. Because humans have never been exposed to these emerging viruses, the resulting symptoms can be much more severe and even lethal in vulnerable populations, as we are observing with the COVID-19 pandemic.

No licensed vaccine is currently available to protect against a coronavirus infection.

Sources: WHO, CDC

Medicago's coronavirus vaccine and antibody candidates

Medicago successfully produced virus-like particles (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene (virus causing the COVID-19 disease). Production of VLPs is the first step in developing a vaccine for COVID-19 which will now undergo preclinical testing for safety and efficacy.

The photos below were taken using an electron microscopy to illustrate the similarity of Medicago's Coronavirus VLP with a wild-type SARS-CoV-2 virus:

Medicago's Plant-Derived Virus-Like Particle (VLP) of SARS-CoV-2

VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack core genetic material which makes them non-infectious and unable to replicate.

Disclaimer: These vaccine and antibody candidates are not approved for human use in any country or region.

Our VLP vaccine candidate for the coronavirus is currently at Phase 3 of clinical development.

Learn more in the section: COVID-19 Programs


Think smarter about a constant public health threat.

Product Type Vaccine

What is seasonal influenza?

Each year, seasonal influenza infection represents a substantial burden of disease, as well as direct and indirect economic burdens worldwide. The severity of influenza morbidity and mortality rates can vary depending on the influenza strain that dominates each season. Some individuals are at an increased risk for influenza infection, including young children, persons with chronic comorbid conditions, and individuals over the age of 65 years.

Most current influenza vaccines demonstrate suboptimal effectiveness against influenza and are produced using live viruses and lengthy adaptation processes that can induce mutations, particularly when grown in eggs. The production process for inactivated split vaccines carries the risk of compromising the integrity of influenza proteins, creating challenges in achieving optimal vaccine immunogenicity and efficacy against influenza viruses.

What is pandemic influenza?

An influenza pandemic is an epidemic of an influenza virus that spreads on a worldwide scale and infects a large proportion of the world population. In contrast to regular seasonal epidemics of influenza, these pandemics occur irregularly – there have been about nine influenza pandemics during the last 300 years. The most infamous case of pandemic flu was the 1918 Spanish Flu.

Medicago's quadrivalent VLP influenza vaccine candidate

Disclaimer: This vaccine is not approved for human use in any country or region and is currently under review by the Health Authorities.

Medicago's candidate plant-derived quadrivalent VLP influenza vaccine is expected to stimulate a balanced antibody and cellular immune response and efficacy against various influenza strains. Our research and trials to date indicate a demonstrated safety profile in adults, including those over the age of 65 years.


The most common cause of acute gastroenteritis in infants and children.

Product Type Vaccine

What is rotavirus?

Rotavirus is very common and highly contagious. The virus causes gastroenteritis, dehydration and potentially death. Children aged 6 months to 2 years of age are most vulnerable - more than 1,200 children die every day of rotavirus before their 5th birthday. Approximately 95% of deaths from rotavirus occur in developing countries.

Medicago's rotavirus vaccine candidate

Disclaimer: This vaccine is not approved for human use in ANY country or region and is currently under clinical investigation.

In partnership with Mitsubishi Tanabe Pharma Corporation, Medicago is developing a rotavirus-like particle vaccine candidate that is currently in Phase 1 studies.

Because this product remains in the clinical trial stage, we continue to investigate its safety and efficacy.